Biopharma ESG Risks from U.S. Pricing doesn't sway our valuation

Presented by

Karen Andersen, Anna Bonomi, Damien Conover, Steven Pearson

About this talk

Join Morningstar, Sustainalytics and the Institute for Clinical and Economic Review (ICER) to discuss the methodology in application to a core risk facing the biopharma group: new U.S. government policies aimed at reducing drug pricing to increase access for patients. Our esteemed panel will discuss their findings from Morningstar's latest research paper, Biopharma ESG Risks from U.S. Pricing doesn't sway our valuation, and: * How ICER recommendations may influence pricing risks for pharma and biotech companies * Sustainalytics’ ESG Risk Rating, with a focus on the exposure dimension of access to basic services Material ESG Issues. * Integration of ESG within Morningstar’s equity research, with regards to the ICER analysis Speakers: Karen Andersen, Strategist, Equity and Credit Analysis, Morningstar Anna Bonomi, Manager, Healthcare & Chemicals Research, Sustainalytics Damien Conover, Director of Equity Strategy, Morningstar Steven Pearson, President, Institute for Clinical and Economic Review (ICER)

Related topics:

More from this channel

Upcoming talks (4)
On-demand talks (174)
Subscribers (41045)
Morningstar Research & Solutions